Atul Saran - EMERGENT BIOSOLUT President

ER4 Stock  EUR 9.54  0.09  0.95%   

President

Mr. Atul Saran is Executive Vice President, Corporationrationrate Development, General Counsel and Corporationrationrate Secretary of the company. Prior to joining Emergent, Mr. Saran served as senior vice president and general counsel at MacroGenics, Inc., from April 2014 to May 2017. Previously, Mr. Saran served in various leadership roles at AstraZeneca plc, and MedImmune, LLC, from 2003 through 2014, including vice president, corporate development and ventures at AstraZeneca and chairman of the MedImmune Ventures investment committee from May 2013 to January 2014 senior vice president, corporate development and ventures from January 2011 to May 2013 and positions of increasing responsibility in the MedImmune legal department from 2003 through 2010, culminating as vice president and deputy general counsel. Before his time at MedImmune, Mr. Saran was an associate attorney in the business and finance group at Hogan Hartson LLP. Mr. Saran is a board member of LogicNets, Inc., a private company. He previously served on the boards of directors for VentiRx Pharmaceuticals, Inc., Xencor, Inc., Inotek Pharmaceuticals, Inc. and Arriva Pharmaceuticals, Inc since 2017.
Age 45
Tenure 7 years
Professional MarksMBA
Saran holds a J.D. from the University of Illinois College of Law, an M.B.A from the MIT Sloan School of Management and a B.S. in Biological Sciences from Stanford University.
EMERGENT BIOSOLUT (ER4) is traded on Berlin Exchange in Germany and employs 18 people.

EMERGENT BIOSOLUT Leadership Team

Elected by the shareholders, the EMERGENT BIOSOLUT's board of directors comprises two types of representatives: EMERGENT BIOSOLUT inside directors who are chosen from within the company, and outside directors, selected externally and held independent of EMERGENT. The board's role is to monitor EMERGENT BIOSOLUT's management team and ensure that shareholders' interests are well served. EMERGENT BIOSOLUT's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, EMERGENT BIOSOLUT's outside directors are responsible for providing unbiased perspectives on the board's policies.
Robert Kramer, CFO, Interim Executive Vice President - Corporate Services Division, Principal Financial and Accounting Officer, Treasurer
Sean Kirk, Executive Vice President Manufacturing and Technical Operations
Katherine Strei, Executive Vice President, Human Resources and Communications, Chief Human Resources Officer
Fuad ElHibri, Executive Chairman of the Board
Sue Bailey, Independent Director
Jerome Hauer, Independent Director
Marvin White, Director
Kathryn Zoon, Independent Director
Atul Saran, Executive Vice President Corporate Development, General Counsel and Corporate Secretary
Seamus Mulligan, Director
George Joulwan, Independent Director
Adam Havey, Executive Vice President and Presidentident - BioDefense Division
Louis Sullivan, Independent Director
Ronald Richard, Lead Independent Director
Zsolt Harsanyi, Independent Director
Richard Lindahl, Chief Financial Officer, Executive Vice President, Treasurer

EMERGENT Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is EMERGENT BIOSOLUT a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in EMERGENT Stock

EMERGENT BIOSOLUT financial ratios help investors to determine whether EMERGENT Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in EMERGENT with respect to the benefits of owning EMERGENT BIOSOLUT security.